Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCERTO: Cediranib + Olaparib in Recurrent Platinum-Resistant Ovarian Cancer
NCT02889900Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib, olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by AstraZeneca. Started Jan 2017; status: completed.
02
Drugs
cediranibolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02889900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02889900.